Abstract
The benefits of hormone replacement therapy (HRT) are numerous: It provides relief of menopausal symptoms, reduces the risk of osteoporosis and accompanying fractures and may potentially aid in the prevention of various other illnesses, including Alzheimer’s disease and cardiovascular disease (CVD) [1 – 4]. Despite the established and potential benefits of HRT, which have been shown to outweigh its possible risks, fewer than one-half of eligible women in the United States are currently using it [1,5. Furthermore, only a fraction of current users will continue therapy for more than 2 years [6]. Part of the reason for this problem with discontinuation is the lack of consistency in the literature regarding risks and benefits. For example, the American Heart Association recently suggested in a position paper that there is no benefit to taking estrogen for secondary prevention of CVD and questioned whether there is any benefit to it in primary prevention [7].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
The Gallup Organization, Inc. The 2000 Gallup Study of Women’s Experiences with Hormone Replacement Therapy. Princeton, NJ: Multi-Sponsor Surveys, Inc. Conducted for Berlex Laboratories, April 2000.
Purdie DW. Consequences of long-term hormone replacement therapy. Br Med Bull 2000; 56:809–23.
Yaffe K, Browner W, Cauley J, Launer L, Harris T. Association between bone mineral density and cognitive decline in older women. J Am Geriatr Soc 1999; 47:1176–82.
Zweifel JE, O’Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997; 22:189–212.
Salamone LM, Pressman AR, Seeley DG, Cauley JA. Estrogen replacement therapy. A survey of older women’s attitudes. Arch Intern Med 1996; 156:1293–97.
Sarrel PM, Dobay B, Witta B. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen-only therapy. J Reprod Med 1998; 43: 847–56.
Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 2001; 104:499–503.
Nerhood RC. Making a decision about ERT/HRT. Evidence to consider in initiating and continuing protective therapy. Postgrad Med 2001; 109:167–70, 173–74,178.
Achieving long-term continuance of menopausal ERT/HRT: Consensus opinion of the North American Menopause Society. NAMS Web site. Available at: http://www.menopause.org/consensus1.htm. Accessed June 4, 2001.
Tosteson AN, Gabriel SE, Kneeland TS, et al. Has the impact of hormone replacement therapy on health-related quality of life been undervalued? J Womens Health Gend Based Med 2000; 9:119–30.
Lobo R, Kelsey J, Marcus R, editors. Menopause: Biology and pathobiology. Burlington, Mass: Academic Press, 2001.
Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception 1996; 54:243–51.
Oelkers W. Drospirenone — A new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur J Contracept Reprod Health Care 2000; 5(Suppl.3): 17–24.
Drospirenone/ethinyl estradiol (Yasmin®): New oral contraceptive promises improved tolerance and less side effects. OBGYN.net Web site. Available at: http://www.obgyn.net/women/articles/MMC/MMC-yasmin.htm. Accessed June 1, 2001.
Oelkers W, Berger V, Bolik A, et al. Dihydrospirenone, a new progestogen with antimineralocorticoid activity: Effects on ovulation, electrolyte excretion, and the reninaldosterone system in normal women. J Clin Endocrinol Metab 1991; 73:837–42.
Data on file, Berlex Laboratories, Inc.
Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the reninaldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80:1816–21.
Blode H, Wuttke W. Loock W, Roll G, Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care 2000; 5:256–64.
Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential. Contraception 1996; 54:243–51.
Krattenmacher R. Drospirenone: Pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62(l):29–38.
Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care 2000; 5(Suppl.3):25–33.
Data on file, Berlex
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Lobo, R.A. (2002). Progestogens: New Approaches. In: Lobo, R.A., Crosignani, P.G., Paoletti, R., Bruschi, F. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 17. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1061-1_20
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1061-1_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5375-1
Online ISBN: 978-1-4615-1061-1
eBook Packages: Springer Book Archive